Australia Stock Exchange release from EMYRIA : EMD-RX5 program advancing Phase 1 clinical trials underway
16/03/2022 22:58
Australia Stock Exchange release from EMYRIA EMD.AX : EMD-RX5 program advancing Phase 1 clinical trials underway
- AU$30.65m
- AU$24.15m
- AU$4.05m